Table 2.

Changes in relevant endpoints occurring after treatment with a deslorelin releasing implant (DRI) and azagly-nafarelin releasing implant (ARI) and comparison in measurements.

Implant	Deslorelin releasing implant (DRI)		Azagly nafarelin releasing implant (ARI)
References	Trigg et al. (14)a; N = 56 Romagnoli et al. (21)b; N = 6		Ludwig et al. (12); N = 8
End point and metric	Time to first reduction (d)	Time to full reduction (d)	Time to first reduction (w)	Time to full reduction (w)
LH concentrations	ND	ND	ND	Week 11c
Testosterone concentrations	Day 23–32a	Day 6–43a Day 64–75a	Week 1	Week 2–3
Testis size	ND	ND	Week 3	Week 17 (by 80%)
Prostatic size	ND	ND	Week 3	Week 5 (by 46%)
Erection allowing sperm collection	Day 22b	Day 30–35b	Week 3	Week 5 (semen from 1/8 dogs could be collected)
Sperm volume	Day 37–47b	Day 64–75b	Week 3 (by 70%)	No sperm collected in 7/8 dogs
Total sperm number in the ejaculate	Day 37–47b	Day 64–75b	Week 3 (by 55%)	No sperm collected in 7/8 dogs
Sperm motility	Day 23–32b	Day 64–75b	ND	No sperm collected in 7/8 dogs
% of Abnormal sperm	NDa	Increased to 70% by Day 35a	Unchanged (at 30%) on week 3	No sperm collected in 7/8 dogs

Note that the durations are expressed in days for the DRI studies vs. in weeks for the ARI studies. ND, not documented.

^aData from Trigg et al. (14), N = 56.

^bRomagnoli et al. (21), N = 6.

^cWeek 11 was the first time point when LH concentrations were assessed and only for the ARI.